PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue The Lancet Infectious Diseases Année : 2020

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Laura Richert
Arnaud Chêne
Odile Launay
Benoit Gamain

Résumé

PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant.
Bundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.
Fichier principal
Vignette du fichier
THELANCETID-HAL version.pdf (2.71 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03161802 , version 2 (02-12-2020)
hal-03161802 , version 1 (08-03-2021)

Identifiants

Citer

Sodiomon B Sirima, Laura Richert, Arnaud Chêne, Amadou T Konate, Cécilia Campion, et al.. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. The Lancet Infectious Diseases, 2020, 20 (5), pp.585-597. ⟨10.1016/S1473-3099(19)30739-X⟩. ⟨hal-03161802v2⟩
558 Consultations
712 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More